CompletedEarly Phase 1

Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT

United States21 participantsStarted 2017-11-08

Plain-language summary

Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with \[18F\]FP-R01-MG-F2 with PET/CT

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕.0 Eligibility Criteria for PSC Patients
✕.1 Inclusion Criteria
✕.2 Exclusion Criteria
✕.0 Eligibility Criteria for Healthy Controls
✕.1 Inclusion Criteria
✕.2 Exclusion Criteria
✕.0 Eligibility Criteria for COVID-19 patients
✕.1 Inclusion Criteria

What they're measuring

SUV max comparison : IPF versus Healthy Lung, PSC versus Healthy Liver, COVID19 versus Healthy Lung

Timeframe: an estimated average of 2 hours

Trial details

NCT IDNCT03183570

SponsorStanford University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-04-25

View on ClinicalTrials.gov More Idiopathic Pulmonary Fibrosis trials